By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Development and commercialization of molecular testing services592.18M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States1.66B97.69%
Europe, Middle East, India, Africa23.88M1.41%
Asia Pacific and Other8.66M0.51%
Americas, excluding U.S.6.62M0.39%